- Home
- PRAA vs PLRX Comparison
PRAA vs PLRX Comparison
Compare PRAA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAA
- PLRX
- Stock Information
- Founded
- PRAA 1996
- PLRX 2015
- Country
- PRAA United States
- PLRX United States
- Employees
- PRAA N/A
- PLRX N/A
- Industry
- PRAA Finance: Consumer Services
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRAA Finance
- PLRX Health Care
- Exchange
- PRAA Nasdaq
- PLRX Nasdaq
- Market Cap
- PRAA 798.8M
- PLRX 641.5M
- IPO Year
- PRAA N/A
- PLRX 2020
- Fundamental
- Price
- PRAA $23.02
- PLRX $14.45
- Analyst Decision
- PRAA Strong Buy
- PLRX Strong Buy
- Analyst Count
- PRAA 2
- PLRX 7
- Target Price
- PRAA $32.00
- PLRX $40.50
- AVG Volume (30 Days)
- PRAA 236.1K
- PLRX 459.1K
- Earning Date
- PRAA 02-13-2025
- PLRX 11-07-2024
- Dividend Yield
- PRAA N/A
- PLRX N/A
- EPS Growth
- PRAA N/A
- PLRX N/A
- EPS
- PRAA 1.10
- PLRX N/A
- Revenue
- PRAA $1,042,710,000.00
- PLRX N/A
- Revenue This Year
- PRAA $39.43
- PLRX N/A
- Revenue Next Year
- PRAA $6.61
- PLRX N/A
- P/E Ratio
- PRAA $20.07
- PLRX N/A
- Revenue Growth
- PRAA 29.69
- PLRX N/A
- 52 Week Low
- PRAA $18.64
- PLRX $10.22
- 52 Week High
- PRAA $31.43
- PLRX $19.62
- Technical
- Relative Strength Index (RSI)
- PRAA 57.05
- PLRX 56.15
- Support Level
- PRAA $20.83
- PLRX $13.14
- Resistance Level
- PRAA $23.04
- PLRX $15.27
- Average True Range (ATR)
- PRAA 0.87
- PLRX 0.75
- MACD
- PRAA 0.17
- PLRX 0.00
- Stochastic Oscillator
- PRAA 83.77
- PLRX 58.27
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.